Biocon since its listing has been an underperformer. It may remain the same for more time to come. Looks like they are looking to sell off some business – APIs.
Also, the Intas USFDA fiasco has cost them dearly, it was 400+ Cr annual business.
| Subscribe To Our Free Newsletter |
